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CLINICAL AND ECONOMIC BENEFITS OF AN
INFECTIOUS DISEASE APPROVAL PROGRAM
Kinky DE, Fishman NO, Morgan AS, Gibson GA
University of Pennsylvania Medical Center, Philadelphia,
PA, USA
A one-month case-control comparison was completed to
evaluate infectious disease costs and outcomes utilizing
an antibiotic management service.
METHODS: Antibiotic approvals were obtained from the
Infectious Disease Pharmacy Specialist (case) or the Infec-
tious Disease fellows (control). Drug selection by the phar-
macy specialist was based on patient-specific and hospital-
specific parameters. Appropriateness of the drug therapy
approved by the service was also reviewed by the antibiotic
management physician. Charts were reviewed after antibi-
otic approval from case or control. They were also reas-
sessed when patients were discharged from the hospital.
Failure, reinfection, superinfection, and death were clinical
outcomes categorized. Cure rates were determined micro-
biologically and clinically. Cost analyses were based on
drug therapy, microbiology, length of treatment days, and
infectious disease consults. Antibiotics administered rea-
sonably without a documented infection were categorized
as "no infection." Patients were excluded if charts were
unattainable or outcome could not be determined.
RESULTS: A total of 255 patients receiving infectious
disease approval was reviewed. Of these, 130 patients
were controls and 125 were cases. Thirty-seven patients
were excluded. Cure rates for the Clinical Pharmacy Spe-
cialist versus the Infectious Disease fellows were 56%
versus 37%. Cost-effectiveness ratios per cure in 1993 US
dollars were $330 for the ID specialist versus $932 for
fellows considering drug costs. Cost-effectiveness ratios,
including total antibiotic management costs were $5,660
versus $11,252, respectively. When ratios were translated
to cost avoidance of the antibiotic management team,
savings were estimated at $94,416 for monthly drug costs
or $1,132,992/year. Total hospital costs savings during
infectious disease management interval were estimated to
be $576,876/month or $6,922,512/year.
CONCLUSIONS: The benefit of the antibiotic manage-
ment team improves cure rates while also decreasing cost
of treatment. This service pays for itself through its sav-
ings in drug and hospital costs while also improving pa-
tient outcomes.
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THE ECONOMIC IMPACT OF A DRUG
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OBJECTIVE: A cost-avoidance model was developed to
determine potential cost savings (PCS) of a drug informa-
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tion service (DIS) that results from answering a drug in-
formation request.
DESIGN: Patient-specific questions received by the drug
information service were reviewed and evaluated. A panel
determined whether or not appropriate drug therapy
would have been employed if the DIS had not been con-
sulted. Potential outcomes of drug information requests
were classified using a decision-tree model. A severity rat-
ing with potential cost avoidance was then attached to
each applicable request to predict PCS of the DIS.
RESULTS: Seventy-seven of the 570 drug information re-
sponses in the six-week study period had assessable PCS
to the institution. During the study interval, PCS were es-
timated to be $196,000. Projected to one year, PCS
reached $1.7 million. Of the savings noted, most were in
the categories of increased monitoring and additional
treatment. Annual PCS using a sensitivity analysis ranged
from $423,601 to $1,922,560 per year.
CONCLUSIONS: This model demonstrates that the DIS
at our institution does provide substantial cost avoidance.
This model may be modified to evaluate PCS in other ar-
eas of pharmacy practice.
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OBJECTIVE: To compare costs of hospitalisation for
lower respiratory tract infection (LRTI) in patients who
received antibiotics before admission versus those who
did not and in patients with and without underlying
chronic obstructive airways disease (COAD).
METHODS: All hospitalisations were analysed in a popu-
lation of 350,000 resident in Tayside during 1993-94.
Three groups of patients were identified by primary dis-
charge diagnosis in 1993-94 and previous admissions
from 1980 to 1992: (1) acute exacerbation of COAD, (2)
LRTI plus a secondary diagnosis of CO AD or previous ad-
mission with COAD, and (3) LRTI but no secondary
COAD or previous admission with COAD. Setting-specific
costs were applied (e.g., general medicine, intensive care,
geriatrics). Dispensed antibiotic prescribing in the 28 days
before admission was identified from all community phar-
macies. Non-parametric statistical tests were used.
RESULTS: Patients with COAD were more likely to have
received antibiotics before admission: COAD (n = 893)
49%; COAD+LRTI (n = 316) 43%; LRTI only (n =
822) 33%. Odds ratio for COAD vs LRTI only 1.90
(95% CI 1.56 to 2.31); COAD+LRTI vs LRTI only 1.50
(95% CI 1.15 to 1.96). Patients who received antibiotics
before admission had lower hospital costs than patients
who did not. Median total costs per admission: COAD
£1050 vs £1164 (p = 0.5); COAD+LRTI £1067 vs
£1354 (p = 0.5); LRTI only £1220 vs £1500; (p =
Abstracts
0.009). Adjusted for community antibiotic prescribing,
the hospital costs of patients with LRTI were significantly
higher than those of patients with COAD (p = 0.001) but
not those of patients with COAD+ LRTI (p = 0.096).
CONCLUSION: Economic models of the potential impact
of different community antibiotics on hospital LRTI costs
will be subject to case mix bias unless they adjust for com-
munity antibiotic use and co-morbidity with COAD.
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The platinum chemotherapeutic compounds (cisplatin
and carboplatin) are widely used in the treatment of ad-
vanced Non-Small Cell Lung Cancer (NSCLC). The in-
troduction of new agents such as paclitaxel and vinorel-
bine has resulted in the development of combination
regimens with improved response rates and survival. Two
commonly used regimens, paclitaxellcarboplatin (TP) and
vinorelbine/cisplatin (NP), are compared in this pharma-
coeconomic analysis.
METHODS: A meta-analysis of available clinical trials
was conducted to estimate the clinical effectiveness of TP
and NP. Literature and physician interviews provided in-
formation on resource utilization and adverse event man-
agement (AEM) for these regimens. Treatment models
were populated with Medicare reimbursement figures to
compare the expected cost of treatment.
RESULTS: The expected cost of the TP and NP regimens
was $19,322 and $20,790, respectively. Although the ef-
ficacy of these regimens has not been compared in a ran-
domized trial, meta-analysis of regimented phase II and
III studies showed no statistically significant differences
in response rates. Therefore, equivalent efficacy is as-
sumed in this cost comparison. A 20% variation in the
cost of underlying resources yielded a 7% standard devia-
tion in results. This sensitivity analysis showed that the
costs of these regimens are insensitive to variations in un-
derlying parameters.
CONCLUSION: This study suggests that TP is the phar-
macoeconomic NSCLC treatment of choice when com-
pared to NP. The analysis reveals that low administration
and AEM costs are the key drivers in the lower treatment
cost of TP.
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